Prestige Consumer Healthcare (Prestige Consumer Healthcare) Cash-to-Debt : 0.05 (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Prestige Consumer Healthcare Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Prestige Consumer Healthcare's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.05.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Prestige Consumer Healthcare couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Prestige Consumer Healthcare's Cash-to-Debt or its related term are showing as below:

PBH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 0.02 Max: 0.1
Current: 0.05

During the past 13 years, Prestige Consumer Healthcare's highest Cash to Debt Ratio was 0.10. The lowest was 0.01. And the median was 0.02.

PBH's Cash-to-Debt is ranked worse than
91.03% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.945 vs PBH: 0.05

Prestige Consumer Healthcare Cash-to-Debt Historical Data

The historical data trend for Prestige Consumer Healthcare's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Prestige Consumer Healthcare Cash-to-Debt Chart

Prestige Consumer Healthcare Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

Get a 7-Day Free Trial

0.02

0.05

0.02

0.04

Prestige Consumer Healthcare Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															0.06	0.04	0.04	0.05	0.05

Competitive Comparison of Prestige Consumer Healthcare's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prestige Consumer Healthcare's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Prestige Consumer Healthcare's Cash-to-Debt falls into.

Prestige Consumer Healthcare Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Prestige Consumer Healthcare's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	58.489	/	(9.76	+	1357.331)
	=	0.04

Prestige Consumer Healthcare's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	63.615	/	(7.838	+	1205.673)
	=	0.05

Prestige Consumer Healthcare (NYSE:PBH) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Prestige Consumer Healthcare Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Prestige Consumer Healthcare's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Prestige Consumer Healthcare (Prestige Consumer Healthcare) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Prestige Consumer Healthcare Inc (NYSE:PBH) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

PBV:Germany

Address

660 White Plains Road, Tarrytown, NY, USA, 10591

Website

https://www.prestigebrands.com

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

Executives

Mary Beth Fritz	officer: Senior VP Quality & Regulatory	660 WHITE PLAINS RD, 2ND FL, TARRYTOWN NY 10591
Ronald M. Lombardi	officer: Chief Executive Officer	660 WHITE PLAINS RD., TARRYTOWN NY 10591
James Darecca	director	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Christine Sacco	officer: Chief Financial Officer	C/O SMART BALANCE, INC., 115 WEST CENTURY ROAD, SUITE 260, PARAMUS NJ 07652
Adel Mekhail	other: EVP, Marketing & Sales	660 WHITE PLAINS RD., 2ND FL, TARRYTOWN NY 10591
William P'pool	officer: See Remarks	2400 WEST LLOYD EXPRESSWAY, EVANSVILLE IL 47721
Celeste A. Clark	director	C/O ADVANCEPIERRE FOODS HOLDINGS, INC., 9987 CARVER ROAD, BLUE ASH OH 45242
Christopher J Coughlin	director
Natale S Ricciardi	director	C/O MORRIS COMMUNICATIONS CORP, 725 BROAD ST., AUGUSTA GA 30903
James M Jenness	director	PO BOX 3599, BATTLECREEK MI 49016-3599
John E Byom	director	660 WHITE PLAINS RD., TARRYTOWN NY 10591
Sheila Hopkins	director	C/O WARNACO INC, 90 PARK AVENUE, NEW YORK NY 10016
Dawn M. Zier	director	600 OFFICE CENTER DRIVE, FORT WASHINGTON PA 19034
Jeffrey Zerillo	officer: Senior VP Operations	660 WHITE PLAINS RD, 2ND FL, TARRYTOWN NY 10591
Timothy Connors	officer: Chief Marketing Officer	660 WHITE PLAINS RD., SUITE 205, TARRYTOWN NY 10591